NCT02019056View on ClinicalTrials.gov

Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Alcoholic Fatty Liver DiseaseAlcoholic Hepatitis
Interventions
DRUG

Placebo /bid P.O

DRUG

MG-1

DRUG

MG-2 : MG1000mg, Placebo /bid P.O

DRUG

metadoxine

Trial Locations (1)

471-701

Hanyang university Hospital, Guri-si

Sponsors

Lead Sponsor

PharmaKing
All Listed Sponsors
lead

PharmaKing

INDUSTRY